Divi's Laboratories Limited (NSE:DIVISLAB)
India
· Delayed Price · Currency is INR 6,045.00
+84.50 (1.42%)
May 9, 2025, 3:29 PM IST
Divi's Laboratories Revenue
Divi's Laboratories had revenue of 23.19B INR in the quarter ending December 31, 2024, with 25.01% growth. This brings the company's revenue in the last twelve months to 90.78B, up 21.16% year-over-year. In the fiscal year ending March 31, 2024, Divi's Laboratories had annual revenue of 78.45B with 1.00% growth.
Revenue (ttm)
90.78B
Revenue Growth
+21.16%
P/S Ratio
17.43
Revenue / Employee
9.32M
Employees
9,741
Market Cap
1,582.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 78.45B | 780.00M | 1.00% |
| Mar 31, 2023 | 77.67B | -11.93B | -13.31% |
| Mar 31, 2022 | 89.60B | 19.90B | 28.56% |
| Mar 31, 2021 | 69.69B | 15.75B | 29.20% |
| Mar 31, 2020 | 53.94B | 4.48B | 9.06% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
| Fortis Healthcare | 75.61B |
Divi's Laboratories News
- 3 months ago - Divi's Laboratories Ltd (BOM:532488) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... - GuruFocus
- 3 months ago - Q3 2025 Divi's Laboratories Ltd Earnings Call Transcript - GuruFocus
- 3 months ago - Divi’s Labs remains our top pick, target price at Rs 6,850 after Q3 results: Citi - Business Upturn
- 5 months ago - Citi reaffirms ‘Buy’ on Divi’s Laboratories, sees buying opportunities amid BioSecure delays - Business Upturn
- 6 months ago - Divi's Laboratories Ltd (BOM:532488) Q2 2025 Earnings Call Highlights: Navigating Growth Amidst ... - GuruFocus
- 6 months ago - Q2 2025 Divi's Laboratories Ltd Earnings Call Transcript - GuruFocus
- 7 months ago - Divis Labs surges over 4.5% on positive brokerage report - Business Upturn
- 7 months ago - Citi initiates Buy on Divis Lab, sees 15% upside in share price - Business Upturn